Regulation of the Inflammatory Response in Cardiac Repair

Nikolaos G. Frangogiannis

Abstract: Myocardial necrosis triggers an inflammatory reaction that clears the wound from dead cells and matrix debris, while activating reparative pathways necessary for scar formation. A growing body of evidence suggests that accentuation, prolongation, or expansion of the postinfarction inflammatory response results in worse remodeling and dysfunction following myocardial infarction. This review manuscript discusses the cellular effectors and endogenous molecular signals implicated in suppression and containment of the inflammatory response in the infarcted heart. Clearance of apoptotic neutrophils, recruitment of inhibitory monocyte subsets and regulatory T cells, macrophage differentiation and pericyte/endothelial interactions may play an active role in restraining postinfarction inflammation. Multiple molecular signals may be involved in suppressing the inflammatory cascade. Negative regulation of toll-like receptor signaling, downmodulation of cytokine responses, and termination of chemokine signals may be mediated through the concerted action of multiple suppressive pathways that prevent extension of injury and protect from adverse remodeling. Expression of soluble endogenous antagonists, decoy receptors, and posttranslational processing of bioactive molecules may limit cytokine and chemokine actions. Interleukin-10, members of the transforming growth factor-β family, and proresolving lipid mediators (such as lipoxins, resolvins, and protectins) may suppress proinflammatory signaling. In human patients with myocardial infarction, defective suppression, and impaired resolution of inflammation may be important mechanisms in the pathogenesis of remodeling and in progression to heart failure. Understanding of inhibitory and proresolving signals in the infarcted heart and identification of patients with uncontrolled postinfarction inflammation and defective cardiac repair is needed to design novel therapeutic strategies. (Circ Res. 2012;110:159-173.)

Key Words: resolution of inflammation ■ myocardial infarction ■ cytokine ■ chemokine ■ mononuclear cells

Over the last 30 years, advanced coronary care and early reperfusion strategies have dramatically improved survival rates in patients suffering an acute myocardial infarction. However, this impressive success has resulted in a larger pool of patients who, having survived the acute infarction, are at risk of developing heart failure. Despite therapeutic advances, the risk of heart failure following myocardial infarction has remained high; in fact, some studies have suggested an increased incidence of postinfarction heart failure in recent decades that parallels the decreasing acute mortality rates. Development of heart failure following myocardial infarction is closely associated with profound alterations in cardiac geometry, function, and structure, also referred to as “ventricular remodeling.” The mo-
The adult human heart contains approximately 4 to 5 billion cardiomyocytes; because the myocardium has negligible endogenous regenerative capacity, loss of a significant amount of cardiac muscle ultimately leads to formation of a scar. Cardiac repair is dependent on a superbly orchestrated sequence of cellular and molecular events that, on the basis of their fundamental properties in regulation of the immune response, may play an important role in the process, despite the absence of direct experimental data documenting their significance. Because of the importance of inflammatory and reparative mechanisms in cardiac remodeling, defects in resolution of inflammation may be responsible for remodeling, injury, and heart failure in a large number of patients surviving a myocardial infarction. Emerging concepts on the significance of endogenous inhibitory pathways in cardiac repair may provide insight into the reasons for the failure of previous strategies targeting the inflammatory response in patients with myocardial infarction.

Initiation of the Post-Infarction Inflammatory Response

The predominant mechanism of cardiomyocyte death in the infarcted heart is coagulation necrosis, although apoptosis is also likely to contribute to cardiomyocyte loss. Cells dying by necrosis release their intracellular contents and initiate an intense inflammatory response by activating innate immune mechanisms. Beyond its traditional role as a "warning system" that allows the host to defend against pathogenic microorganisms by discriminating "self" from "nonself," innate immunity also serves as a sophisticated molecular network that senses host-

<table>
<thead>
<tr>
<th>Non-standard Abbreviations and Acronyms</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIS</td>
</tr>
<tr>
<td>CRP</td>
</tr>
<tr>
<td>Del-1</td>
</tr>
<tr>
<td>GDF</td>
</tr>
<tr>
<td>ICAM</td>
</tr>
<tr>
<td>IL</td>
</tr>
<tr>
<td>IL-1Ra</td>
</tr>
<tr>
<td>IRAK</td>
</tr>
<tr>
<td>JAK</td>
</tr>
<tr>
<td>LFA-1</td>
</tr>
<tr>
<td>MCP</td>
</tr>
<tr>
<td>MMP</td>
</tr>
<tr>
<td>MyD88</td>
</tr>
<tr>
<td>NF-κB</td>
</tr>
<tr>
<td>PAI</td>
</tr>
<tr>
<td>PD1</td>
</tr>
<tr>
<td>PDGF</td>
</tr>
<tr>
<td>PTX3</td>
</tr>
<tr>
<td>RAGE</td>
</tr>
<tr>
<td>SHP1</td>
</tr>
<tr>
<td>SOCS</td>
</tr>
<tr>
<td>STAT</td>
</tr>
<tr>
<td>TGF</td>
</tr>
<tr>
<td>TIMP</td>
</tr>
<tr>
<td>TLR</td>
</tr>
<tr>
<td>TNF</td>
</tr>
<tr>
<td>Tregs</td>
</tr>
<tr>
<td>TSP</td>
</tr>
<tr>
<td>VCAM</td>
</tr>
<tr>
<td>VEGF</td>
</tr>
</tbody>
</table>
Inflammation and Cardiac Repair

The consequences of unrestrained inflammation in the infarcted heart. Repair of the infarcted heart is dependent on timely suppression of the postinfarction inflammatory response and on resolution of the inflammatory infiltrate. A-C, Histopathologic illustration of induction, suppression and resolution of the postinfarction inflammatory response in a canine model. Dual immunohistochemical staining combines staining for Mac387 (red), a myeloid cell marker that labels neutrophils and monocytes (but not mature macrophages), serving as a measure of active leukocyte recruitment in inflamed tissues and staining for PM-2K, a mature macrophage marker that is not expressed in newly-recruited monocytes. After 24 hours of reperfusion, abundant newly recruited myeloid cells are identified in the infarct; however; their number decreases significantly after 7 days reflecting suppression of active inflammatory cell recruitment. At this stage, PM-2K+ mature macrophages are the predominant leukocyte type in the infarct. After 28 days of reperfusion, resolution of the leukocyte infiltrate is noted. D, Expected effects of uncontrolled and excessive inflammation on the cell types involved in cardiac repair. Prolongation or accentuation of the inflammatory reaction may result in increased leukocyte activation, enhanced adhesiveness and permeability of endothelial cells, acquisition of a matrix-degrading phenotype by fibroblasts, and cardiomyocyte apoptosis. E, Impact of the cellular effects of overactive, prolonged, or poorly contained inflammation on the infarcted heart. Cardiac rupture, formation of ventricular aneurysms, increased dysfunction, and adverse dilative remodeling could result from defective regulation of the postinfarction inflammatory response.

Derived “danger signals” released by necrotic cells, or by damaged extracellular matrix, activating inflammatory pathways while remaining unresponsive to nondangerous motifs.

In the infarcted myocardium several innate immune pathways are activated. Generation of damage-associated molecular patterns by necrotic cells and matrix fragments activates membrane-bound toll-like receptors (TLRs); the role of TLR signaling in postischemic inflammation has been recently reviewed in Circulation Research. Other innate immune pathways including the high-mobility group box 1, the receptor for advanced glycation end-products (RAGE), and the complement species production and potassium efflux appear to play an important role in inflammasome activation in cardiac fibroblasts undergoing hypoxia/reoxygenation protocols.

Chemokine induction is a prominent feature of the postinfarction inflammatory response. Chemokines provide directional signals for extravasation of leukocyte subpopulations in the infarcted myocardium. Both CC chemokines that function as potent mononuclear cell chemoattractants, and ELR motif-containing CXC chemokines that attract neutrophils, are rapidly and markedly upregulated in the infarcted myocardium. Chemokines released in the infarct are immobilized to glycosaminoglycans on the endothelial surface and in the extracellular matrix; these interactions generate localized high chemokine concentrations in areas of injury despite the shear forces caused by blood flow. Through interactions with chemokine receptors expressed by leukocyte subpopulations, the chemokine expression profile in the infarcted myocardium determines the composition of the leukocytic infiltrate. Neutrophils are recruited very early after cardiac injury, proinflammatory monocytes and lymphocytes follow. Leukocyte transmigration in the infarcted myocardium requires adhesive interactions with activated vascular endothelial cells and involves a cascade of molecular steps. First, leukocytes are “captured” from the rapidly flowing bloodstream and roll on vascular endothelial cells through interactions involving a family of cell adhesion receptors, the selectins. The next step is stable arrest, characterized by firm adhesion of the leukocyte on the endothelial surface mediated through chemokine-induced activation of leukocyte integrins.
large pool of short-lived inflammatory cells, programmed to undergo apoptosis (Figure 2). Their removal from the infarcted myocardium by macrophages, prodigious phagocytic cells, is likely to activate potent inhibitory pathways. Neutrophil life-span may be somewhat prolonged in the proinflammatory environment of the infarct due to the effects of tumor necrosis factor (TNF)-α and IL-1β, mediators capable of extending granulocyte survival. However 3 to 7 days after the acute event the neutrophil infiltrate resolves in both mouse and canine infarcts as most granulocytes undergo apoptosis. Like all dying cells, apoptotic neutrophils attract their scavengers by producing "find me" signals (such as lipid mediators and nucleotides) and express "eat me" signals in their surface (such as lysophosphatidylcholine) promoting their own clearance. Apoptotic granulocytes are capable of attenuating inflammation through 2 distinct mechanisms. First, dying neutrophils release mediators that inhibit further neutrophil recruitment, such as annexin A1 and lactoferrin. These mediators also act as chemoattractants for phagocytic cells thus promoting resolution of the neutrophil infiltrate. Second, uptake of apoptotic neutrophils activates an anti-inflammatory program in macrophages promoting induction and release of IL-10, transforming growth factor (TGF)-β and of proresolving lipid mediators (such as lipoxins and resolvins). Although the fundamental biology of the inflammatory response suggests that macrophage-mediated clearance of apoptotic infiltrating neutrophils may be crucial in triggering anti-inflammatory and proresolving signals, the significance of these interactions in the infarcted heart has not been investigated.

Monocyte Subpopulations as Suppressors of the Inflammatory Response

Through their ability to produce and secrete inhibitory mediators, such as IL-10 and TGF-β, suppressive monocyte subpopulations are ideally suited as negative regulators of inflammation. Over the last decade our understanding of the involvement of monocytes in immune responses has evolved revealing their functional heterogeneity and their complex roles in inflammatory conditions. In mice 2 main subsets of monocytes have been documented: 1) a subpopulation of Ly6Chi inflammatory monocytes that migrate into injured tissues and exhibit high levels of expression of the CC chemokine receptor CCR2, whereas expressing low levels of the fractalkine receptor CX3CR1 (Ly-6C^hiCCR2^hi/CX3CR1^low^) and 2) a smaller subset of Ly6C^low^/CCR2^low/neg/CX3CR1^hi^ "resident" monocytes.

Monocyte subpopulations with distinct modulatory effects on inflammatory responses have also been described in humans: human CD16- monocytes express high levels of CCR2 and have proinflammatory properties resembling murine Ly6C^hi^ cells. Following myocardial infarction early induction of the CCR2 ligand, monocyte chemotactant protein (MCP)-1 drives recruitment of proinflammatory Ly-6C^hi^ monocytes; these cells scavenge debris and secrete inflammatory cytokines and matrix-degrading proteases. Repression of inflammatory signals is associated with recruitment of Ly6C^lo/CX3CR1^hi^ monocytes that produce angiogenic mediators and contribute to infarct healing. Whether specific chemokine/chemokine receptor interactions induce recruitment of suppressive monocyte subpopulations ensuring timely repression of postinfarction inflammation in the healing myocardium remains unknown. Monocyte hetero-
geneity has also been demonstrated in human patients with acute myocardial infarction. Circulating proinflammatory CD14+/CD16− cells showed an early peak in patients with ST elevation myocardial infarction and were negatively associated with recovery of function.25

**Macrophage Heterogeneity and Resolution of Postinfarction Inflammation**

In the proinflammatory environment of the healing infarct, upregulation of macrophage-colony stimulating factor induces monocyte to macrophage differentiation.26 During resolution of postinfarction inflammation macrophages are capable of exerting both inhibitory actions by secreting mediators that suppress inflammation, and proresolving effects through the removal of inflammatory leukocytes. Despite extensive evidence demonstrating the abundance of macrophages in the infarcted heart and their potential to regulate the inflammatory response, our knowledge on the role of macrophage-mediated interactions in repression of inflammatory signals and in resolution of the leukocyte infiltrate remains extremely limited. The key for understanding the role of macrophages in cardiac repair lies in identification of time-dependent alterations in phenotype and function of macrophage subpopulations. Mirroring the classification of T-helper cells in Th1 and Th2 types, 2 distinct macrophage subsets have been recognized:27 the classically activated M1 macrophages that exhibit enhanced microbicidal capacity and secrete large amounts of proinflammatory mediators and the alternatively activated M2 macrophages that show increased phagocytic activity and a phenotype of high expression of IL-10, the decoy type II IL-1 receptor and IL-1 receptor antagonist (IL-1Ra).28 The polarized M1/M2 classification clearly represents an oversimplification; it is increasingly recognized that inflamed tissues contain a wide spectrum of macrophage subpopulations with distinct properties and functional characteristics.29 Mosser and Edwards have suggested a functional classification of macrophages that distinguishes in addition to the proinflammatory, classically activated cells, subpopulations of regulatory and reparative macrophages.30 In the complex environment of the infarcted heart, the spatially and temporally regulated expression of a variety of cytokines, chemokines, and growth factors is likely to affect macrophage phenotype leading to sequential generation of many distinct subsets. During the resolution phase of inflammation, macrophages that phagocytose apoptotic neutrophils may acquire a regulatory phenotype, expressing large amounts of inhibitory mediators and promoting suppression of the inflammatory response. Unfortunately, experimental studies investigating the role of macrophage subpopulations in the healing infarct have not been performed. The phenotypic characteristics, molecular profile, and the functional role of these cells remain unknown.

**Regulatory T Cells as Suppressors of Postinfarction Inflammation**

Because of the tight regulation of constitutive lymphocyte homing, homeostatic circulation of naïve lymphocytes is restricted to secondary lymphoid organs.30 In contrast, in inflammatory states, chemokine induction and activation of adhesive lymphocyte/endothelial cell interactions result in intense infiltration of inflamed nonlymphoid tissues with lymphocytes. Effector T cells are recruited in sites of injury where they release proinflammatory mediators. However, the immune system also produces a population of T cells with suppressive properties that serves to keep in check the activation and expansion of the immune response. These cells, termed regulatory T cells (Tregs) are a CD4+/CD25+ subset of T lymphocytes with potent suppressive properties.31 Tregs play an essential role in immune homeostasis; depletion of Tregs elicits autoimmunity and augments immune responses to nonself antigens.32 Beyond their essential role in the pathogenesis of autoimmune diseases, Tregs also appear to modulate immune responses to infection and malignancy and have been implicated in suppression of the atherosclerotic process.33 Recent evidence suggests that Tregs may play a role in suppression of the postinfarction inflammatory response (Figure 3).34 Mice with genetic disruption of the chemokine receptor CCR5 exhibited accentuated inflammatory response and enhanced matrix metalloproteinase (MMP) activity following reperfused myocardial infarction. Increased inflammation in CCR5 null animals was associated with reduced infiltration of the infarcted myocardium with CD4+/CD25+ Tregs.34 Although a causative relation between defective recruitment of Tregs and enhanced remodeling has not been established, Tregs may modulate macrophage phenotype and suppress postinfarction inflammation by secreting soluble mediators, such as IL-10 and TGF-β, or through contact-dependent pathways.34 On the other hand, the anti-inflammatory effects of CCR5 signaling may be mediated through Treg-independent mechanisms. CCR5 signaling may suppress inflammation through chemotraction of inhibitory monocyte subsets; moreover, increased CCR5 expression in apoptotic leukocytes may serve as a molecular sink for inflammatory chemokines.35

**Pericyte Coating May Control Inflammation by Promoting Vascular Maturation**

During the inflammatory phase of infarct healing, vascular endothelial cells synthesize and present chemokines while expressing adhesion molecules on their surface. Adhesive interactions between endothelial cells and leukocytes are required for recruitment of inflammatory cells into the infarct. As the inflammatory infiltrate is replaced by granulation...
tissue, extensive angiogenesis occurs resulting in formation of neovessels that provide oxygen and nutrients to the highly dynamic and metabolically active cells of the healing wound. Because vascular endothelial growth factor is markedly induced within the first few hours after infarction, early neovessels in the infarcted heart are hyperpermeable and proinflammatory,\textsuperscript{36} lacking a pericyte coat. As a mature scar is formed, the infarct vasculature undergoes a maturation process that plays an important role in stabilization of the wound (Figure 4).\textsuperscript{37} Some of the infarct neovessels acquire a coat comprised of pericytes and smooth muscle cells, whereas uncoated endothelial cells undergo apoptosis. Acquisition of a mural cell coat reduces vascular permeability and decreases angiogenic potential of the vessels, contributing to the formation of a stable scar. The interactions between pericytes and endothelial cells that result in vascular coating involve platelet derived growth factor (PDGF)-BB–PDGFR–\(\beta\) signaling.\textsuperscript{38} PDGFR–\(\beta\) blockade resulted in impaired maturation of the infarct vasculature, enhanced capillary density, and promoted formation of a significant number of dilated uncoated vessels. Defective vascular maturation on PDGFR–\(\beta\) inhibition was associated with increased and prolonged extravasation of red blood cells and monocyte/macrophages, suggesting increased permeability and uncontrolled inflammation; these defects were associated with decreased collagen content in the healing infarct. Thus, pericyte coating is an important step for suppression of granulation tissue formation following myocardial infarction, and promotes resolution of inflammation and stabilization of the scar. Whether pericytes secrete soluble mediators, or directly signal to promote endothelial cell quiescence, is unknown.

**Extracellular Matrix as a Regulator of the Postinfarction Inflammatory Response**

Beyond their obvious contribution in providing mechanical support to the infarcted heart, extracellular matrix proteins also act as key regulators of the inflammatory response. The dynamic alterations in the extracellular matrix composition critically regulate inflammatory activity by modulating phenotype function and gene expression in fibroblasts, endothelial cells, and leukocytes. In the early stages following infarction, generation of matrix fragments enhances cytokine and chemokine synthesis, while deposition of a plasma-derived provisional matrix provides a scaffold for leukocyte infiltration and may transduce proinflammatory signals.\textsuperscript{39} Clearance of matrix fragments from the injured tissue appears to be an essential step for resolution of inflammation and, much like removal of apoptotic cells, may activate inhibitory pathways.\textsuperscript{40} Hyaluronan fragments are potent activators of inflammatory pathways; their clearance through interactions with the transmembrane adhesion molecule CD44 is important for resolution of chronic inflammation.\textsuperscript{41} Extensive disruption of the myocardial hyaluronan network is observed in myocardial infarcts. CD44 expression is markedly induced in leukocytes, wound myofibroblasts, and vascular cells infiltrating the infarct; CD44 absence is associated with enhanced and prolonged neutrophil and macrophage infiltration and increased expression of proinflammatory cytokines in the infarcted myocardium.\textsuperscript{42} These observations suggest that CD44-mediated removal of hyaluronan fragments may be essential to restrain the inflammatory response.

The temporally and spatially restricted expression of fibronectin and matricellular proteins in the infarcted heart may provide an additional matrix-related mechanism for regulation of inflammation. The matricellular protein thrombospondin (TSP)–1, a crucial TGF–\(\beta\) activator with potent angiostatic and anti-inflammatory properties, is strikingly upregulated in the border zone of the infarct.\textsuperscript{43} TSP–1 has been shown to inhibit proliferation and migration of inflammatory cells in the infarcted heart and showed expansion of the inflammatory infiltrate into the noninfarcted area. Prolonged and expanded postinfarction inflammation in TSP–1 null animals...
resulted in increased adverse remodeling of the ventricle.43 These findings suggest an important role for TSP-1 in suppression and containment of the inflammatory reaction following infarction. Localized induction of TSP-1 in the infarct border zone may form a “barrier” preventing expansion of the inflammatory infiltrate in the noninfarcted area. The mechanisms involved in TSP-1-mediated inhibition of inflammation remain unknown and may involve impaired TGF-β activation or direct anti-inflammatory actions.

**Molecular Pathways Involved in Repression and Resolution of Postinfarction Inflammation**

Negative Regulation of TLR Signaling

Considering the extensive collateral damage that may be induced by stimulation of a broad spectrum of inflammatory signals due to uncontrolled TLR activation, it is not surprising that several distinct pathways have evolved to negatively regulate TLR-mediated responses. Over the last 10 years, many molecules have been identified as inhibitors of TLR signaling at multiple levels; detailed discussions of these pathways are provided in fundamental immunologic reviews.44 Disruption of some of these negative regulators results in uncontrolled inflammation suggesting their essential role in restraining TLR-mediated immune responses. Tyrosine phosphatases can negatively regulate TLR responses. SH2-containing protein tyrosine phosphatase 1 negatively regulates TLR-mediated induction of proinflammatory cytokines through activation of NF-κB and MAPK.45 SHP2 also has inhibitory actions, but in a more specific manner limiting TLR3-induced inflammatory responses without affecting TLR2 or TLR9 signaling.46 Interleukin-1 receptor associated kinase (IRAK)-M, is the only member of the IRAK family that lacks kinase activity, thus functioning as a decoy that negatively regulates TLR- and IL-1-mediated inflammatory responses. IRAK-M null mice exhibit accentuated inflammatory responses following bacterial and viral infections and IRAK-M deficient macrophages display enhanced activation of IL-1/TLR signaling.47 IRAK-M acts by preventing IRAK-1 from dissociating from the MyD88 complex thus inhibiting NF-κB activation. Additional inhibitory actions of IRAK-M are IRAK-1-independent, mediated through stabilization of MAPK phosphatase-1 that negatively regulates TLR2-induced p38 phosphorylation.48 MyD88s, a lipopolysaccharide-inducible spliced form of MyD88 that lacks the IRAK4-interacting domain is also involved in negative regulation of TLR signaling by inhibiting IRAK-4-mediated IRAK-1 phosphorylation.49 The TAM receptor protein tyrosine kinases have been recently recognized as inhibitors of TLR signaling. TAM ligands activate a type I interferon receptor pathway leading to signal transducers and activators of transcription (STAT)1 activation and induction of suppressor of cytokine signaling (SOCS)-1 and SOCS-3, which block TLR signaling. Defective TAM signaling results in interruption of this inhibitory pathway and potentiates TLR signaling.50 Receptor interacting protein 3, a kinase that inhibits receptor interacting protein 1-induced NF-κB signaling,51 activating transcription factor 3, the autophagy-related molecule Atg16L1, and the TLR-inducible zinc finger protein A20 and Zc3h12a have also been identified as essential negative regulators of TLR signaling in vivo.52 Despite the fundamental evidence demonstrating a role for all these pathways in preventing uncontrolled TLR signaling, their contribution in regulation of postinfarction inflammation has not been investigated.

Negative Regulation of Cytokine Signaling

Binding of cytokines to their receptors results in activation of intracellular cascades involving a family of tyrosine kinases called janus activated kinases (JAKs). Activated JAKs phosphorylate tyrosine residues in the cytoplasmic portion of cytokine receptors and serve as docking platforms for intracellular proteins. Most of the cytokine-activated intracellular proteins belong to the family of STAT and after tyrosine phosphorylation by JAKs then dimerize and translocate to the nucleus where they initiate transcription. Negative regulation of cytokine signaling may involve several distinct mechanisms. First, natural endogenous cytokine inhibitors may be upregulated to suppress specific responses. IL-1Ra, an endogenous competitive inhibitor of IL-1–driven inflammation, plays an important role in preventing autoimmune inflammatory responses. Although the role of endogenous IL-1Ra in suppression and resolution of the postinfarction inflammatory response has not been dissected, IL-1Ra overexpression exerts protective actions on the infarcted heart.53 Second, expression and activation of decoy receptors (such as the type II IL-1 receptor) may serve as molecular sinks or scavengers for cytokines (Figure 5). The importance of this regulatory mechanism in regulating cytokine-driven inflammation following infarction has not been tested. Third, endocytosis of signaling-competent receptors followed by proteasomal degradation of signaling molecules may play an important role in preventing uncontrolled cytokine actions. Finally, negative regulation of cytokine signaling may involve induction of molecular signals that actively terminate cytokine signaling by dephosphorylating JAKs (Figure 6).54 Several phosphatases have been implicated in negative regulation of cytokine signaling, including SHP-1, the protein tyrosine phosphatase protein tyrosine phosphatase 1B and the T cell protein tyrosine phosphatase. Members of the protein inhibitor of activated STAT family inhibit cytokine-induced gene expression by blocking the DNA binding ability of STAT proteins.55 Perhaps the best studied family of cytokine inhibitors is the
SOCS family of inhibitory proteins. Cytokine inducible SH2 containing protein (CIS), the first member of the SOCS family, acts as a negative regulator of STAT5 signaling. The development of CIS knockout animals suggested that most CIS-mediated functions may be redundant in vivo because of compensation by other SOCS proteins. SOCS-1 is the best studied member of the SOCS family. Like most SOCS proteins, SOCS-1 is inducible on stimulation of the cells with cytokines or bacterial components. A wide range of cytokines can stimulate SOCS-1 synthesis, including mediators that activate JAK/STAT and growth factors that act independently of STAT signaling (such as TGF-β). SOCS-1 exhibits broad inhibitory effects on cytokine signaling, mediated through binding with the activation loop of JAKs and suppression of their kinase activity. JAK-independent suppressive actions of SOCS-1 have also been reported. The generation of SOCS-1 null mice revealed an essential role for SOCS-1 in suppression of inflammation. SOCS-1 is inducible in both normal and stimulated cells with cytokines or bacterial components. A wide range of cytokines can stimulate SOCS-1 synthesis, including mediators that activate JAK/STAT and growth factors that act independently of STAT signaling (such as TGF-β). SOCS-1 exhibits broad inhibitory effects on cytokine signaling, mediated through binding with the activation loop of JAKs and suppression of their kinase activity.

JAK-independent suppressive actions of SOCS-1 have also been reported. The generation of SOCS-1 null mice revealed an essential role for SOCS-1 in suppression of inflammation. SOCS-1 is inducible in both normal and stimulated cells with cytokines or bacterial components. A wide range of cytokines can stimulate SOCS-1 synthesis, including mediators that activate JAK/STAT and growth factors that act independently of STAT signaling (such as TGF-β). SOCS-1 exhibits broad inhibitory effects on cytokine signaling, mediated through binding with the activation loop of JAKs and suppression of their kinase activity. JAK-independent suppressive actions of SOCS-1 have also been reported. The generation of SOCS-1 null mice revealed an essential role for SOCS-1 in suppression of inflammation. SOCS-1 is inducible in both normal and stimulated cells with cytokines or bacterial components. A wide range of cytokines can stimulate SOCS-1 synthesis, including mediators that activate JAK/STAT and growth factors that act independently of STAT signaling (such as TGF-β). SOCS-1 exhibits broad inhibitory effects on cytokine signaling, mediated through binding with the activation loop of JAKs and suppression of their kinase activity.

Figure 6. Negative regulation of cytokine signaling. Intracellular signals such as the suppressor of cytokine signaling (SOCS) proteins and several phosphatases interfere with janus activated kinases (JAK)-signal transducers and activators of transcription (STAT) signaling inhibiting cytokine responses (see text). TCPTP indicates T cell protein tyrosine phosphatase; SHP1, SH2-containing protein tyrosine phosphatase 1; PTB1B, protein tyrosine phosphatase 1B; PIAS, protein inhibitor of activated STAT; P, phosphorylation.

Pentraxin-3 as a Negative Regulator of Inflammation

The members of the pentraxin family constitute the prototypic components of the humoral arm of the innate immune system, representing the functional ancestors of antibodies and playing an important role in discrimination between self and nonself and in recognition of danger signals. C-reactive protein (CRP) and serum amyloid peptide are the classic short pentraxins, prototypic acute phase proteins released by hepatocytes on inflammatory injury. CRP injection in an experimental model of coronary occlusion accentuates cardiomyocyte injury by activating the complement cascade; CRP inhibition has been suggested as a promising therapeutic strategy in myocardial infarction. The prototypic long pentraxin (PTX), PTX3, on the other hand, is upregulated in the infarcted heart and appears to play an important role in negative regulation of the inflammatory reaction. PTX3 null mice exhibit accentuated cardiac injury in a model of reperfused infarction, attributed at least in part to accentuated inflammation resulting in a larger no-reflow area. Although immobilized PTX3 activates the complement cascade, in the fluid phase, PTX3 can sequester C1q preventing complement activation. Moreover, in inflamed tissues PTX3 released by neutrophils binds to P-selectin and inhibits leukocyte recruitment, while suppressing the proinflammatory actions of platelets. Downregulation of the complement cascade, disruption of selectin-mediated rolling, and inhibition of platelet-induced inflammation may contribute to the inhibitory effects of PTX3 in the postinfarction inflammatory response.
for termination of chemokine-driven inflammation in vivo. Duffy antigen receptor for chemokines is expressed on blood vessels and erythrocytes and limits endotoxin-induced inflammation.\(^6\) D6 is expressed on the lymphatic endothelium and functions as a mechanism for chemokine clearance in cutaneous inflammation.\(^6\) Whether chemokine decoy receptors are expressed and play a role in myocardial inflammation remains unknown. It should be noted that under certain conditions, signaling-competent chemokine receptors may function as decoy receptors. In a model of peritonitis CCR5 expression was markedly increased in apoptotic neutrophils and lymphocytes serving as a molecular trap for chemokines.\(^3\) This mechanism may provide an alternative explanation for the accentuated inflammatory response observed in CCR5 null animals following myocardial infarction.\(^3,4\)

### Lipid Mediators in Resolution of Postinfarction Inflammation

During acute inflammation, leukocytes synthesize a wide range of lipid-derived mediators that regulate the inflammatory response. Prostaglandins and leukotrienes are released early following tissue injury and exert proinflammatory actions.\(^7\) During the resolution phase of inflammation, a recently-described genus of specialized proresolving mediators is induced,\(^7\) comprised of 4 distinct families: lipoxins, resolvins, protectins, and maresins. These mediators have potent and direct anti-inflammatory and proresolving functions, limiting inflammatory leukocyte recruitment, while promoting clearance of apoptotic neutrophils by macrophages. Lipoxins A4 and B4 are lipoxygenase-derived eicosanoids; their appearance in inflammatory exudates is associated with resolution of inflammation. Lipoxins are anti-inflammatory at nanomolar concentrations inhibiting chemokine-driven recruitment of both granulocytes and monocytes.\(^2\) At the site of inflammation, lipoxins also stimulate macrophages to ingest and clear apoptotic neutrophils\(^3\) exerting proresolving actions. Resolvins are enzymatically derived from the major omega-3 fatty acids EPA (E-series resolvins) and DHA (D-series resolvins), or as aspirin-triggered epimers generated through cyclooxygenase-2-dependent reactions in the presence of aspirin. Resolvins exert potent anti-inflammatory effects by attenuating neutrophil transendothelial migration and tissue infiltration,\(^4\) while inducing resolution of inflammation by enhancing neutrophil clearance from sites of injury. Protectin D1 (PD1) is generated from the biosynthetic intermediate 17S-hydroxy-DHA and is also released in inflammatory exudates. PD1 possesses potent immunomodulatory functions in vitro and in vivo marked by inhibiting inflammation.\(^5\) Maresins, a newly discovered family of anti-inflammatory mediators, were isolated from exudates of mouse peritonitis and were identified as inhibitors of inflammation and potent proresolving agents.\(^6\) Their mechanism of function remains largely unknown. Renal and pulmonary ischemia and reperfusion induce up-regulation of D series resolvins, PD1, and lipoxins.\(^7,8\) Administration of exogenous anti-inflammatory eicosanoids has demonstrated potent anti-inflammatory effects in experimental models of ischemia and reperfusion. Moreover, a recent experimental study reported protective effects of exogenous administration of resolving E1 in the ischemic and reperfused myocardium.\(^2\) However, evidence on the involvement of lipid-derived mediators in resolution of the postinfarction myocardial inflammatory response is lacking.

### Inhibition of Leukocyte Adhesion Cascades

Inflammatory responses are dependent on activation of adhesive interactions between endothelial cells and leukocytes. During suppression of inflammation, the adhesive properties of both endothelial cells and leukocytes are markedly attenuated. Up-regulation of pleiotropic inhibitory cytokines that suppress adhesion molecule expression, such as IL-10 and TGF-β, may play an important role in downmodulation of adhesive interactions. In addition, recent evidence has identified endogenous endothelial cell-derived integrin ligands that serve as potent inhibitors of leukocyte adhesion.\(^3\) Developmental endothelial locus (Del)-1 is secreted by endothelial cells and binds to the LFA-1 integrin functioning as an antagonist of leukocyte/endothelial cell adhesion. In vivo, loss of Del-1 is associated with accentuated endotoxin-mediated pulmonary inflammation.\(^8\) Whether Del-1, or other endogenous inhibitors of adhesion, is involved in regulation of the postinfarction inflammatory response remains unknown.

### Inhibitory Cytokines IL-10 and TGF-β

Extensive evidence has documented the role of the pleiotropic cytokines IL-10 and TGF-β in regulation of the immune response.\(^2\) TGF-β1 is essential in restraining relentless T-cell responses in peripheral tissues.\(^2\) IL-10, on the other hand, is critically involved in immune tolerance limiting immune responses to foreign antigens. Although both mediators have been implicated in regulation of the postinfarction inflammatory response, their role is complex as they affect most cell types involved in cardiac repair in a context-dependent manner.

#### IL-10

IL-10, a cytokine predominantly expressed by activated T lymphocytes and stimulated macrophages, possesses potent anti-inflammatory properties and prevents excessive inflammatory reactions.\(^3\) Among the different cell types affected by IL-10, mononuclear cells appear to be particularly modified in regard to their function, morphology, and phenotype. IL-10 inhibits the production of proinflammatory cytokines and chemokines by endotoxin-stimulated macrophages suppressing the inflammatory response. Furthermore, IL-10 may play a significant role in extracellular matrix remodeling by promoting tissue inhibitor of metalloproteinases (TIMP)-1 synthesis, contributing to stabilization of the matrix.\(^4\) The suppressive effects of IL-10 on mononuclear cells are dependent on STAT3 signaling. Published evidence implicates IL-10 in regulation of the postinfarction inflammatory reaction. IL-10 mRNA and protein is markedly upregulated in reperfused canine and murine myocardial infarction exhibiting a prolonged time course of expression.\(^5,15\) T-cell subsets and macrophage subpopulations appear to be responsible for IL-10 synthesis in the infarcted myocardium.\(^5,6\) In a canine model IL-10 upregulation in the infarcted myocardium was associated with decreased expression of proinflammatory cytokines; in vitro, IL-10 released in the cardiac interstitium was responsible for
induction of TIMP-1 mRNA by isolated canine mononuclear cells suggesting a role in matrix stabilization.\textsuperscript{85} Two independent loss-of-function studies in mouse models of reperfused infarction have produced somewhat contradictory results. Yang and coworkers suggested that IL-10\textsuperscript{−/−} mice had markedly increased mortality and exhibited an enhanced inflammatory response following reperfused myocardial infarction showing accentuated neutrophil recruitment, elevated plasma levels of TNF-α and higher tissue expression of ICAM-1.\textsuperscript{87} In contrast, Zymek and coworkers found much more subtle differences in the postinfarction inflammatory response between IL-10 null and wildtype animals.\textsuperscript{88} Infarcted IL-10\textsuperscript{−/−} mice and wildtype littermates exhibited comparable survival following infarction. Although IL-10 disruption was associated with higher peak TNF-α and MCP-1 mRNA levels in the infarcted heart, repression of proinflammatory cytokine and chemokine synthesis and resolution of the neutrophil infiltrate were not affected. IL-10 gene disruption did not alter fibrous tissue deposition and dilative remodeling of the infarcted heart.\textsuperscript{88} Taken together the findings suggest that IL-10 injection in the infarcted heart may play a role in controlling the acute inflammatory response but is not involved in clearance of the inflammatory infiltrate and resolution of inflammation. However, administration of exogenous IL-10 significantly reduced inflammation and improved cardiac remodeling following myocardial infarction in mice.\textsuperscript{89}

**Members of the TGF-β Superfamily**

The TGF-βs are some of the most pleiotropic and multifunctional peptides known and exert potent and direct effects on all cell types involved in the inflammatory and reparative response following myocardial infarction. The cellular actions of TGF-β are not only dependent on the cell type but also on its state of differentiation and on the cytokine milieu.\textsuperscript{90} Development of mice with genetic disruption of the TGF-β1 gene has revealed a critical role of TGF-β in homeostasis of the immune system. Approximately 50% of TGF-β1 null mice die in utero due to defective yolk sac vasculogenesis and hematopoiesis.\textsuperscript{85} The remaining animals develop to term and show no gross developmental abnormalities, but about 2 to 4 weeks after birth they succumb to a wasting syndrome associated with multifocal inflammation and massive lymphocyte and macrophage infiltration in many organs, but primarily in the heart and lungs.\textsuperscript{92} The inflammatory response in TGF-β1 null mice is eliminated by depleting mature T cells.\textsuperscript{93} In vitro and in vivo studies suggest that TGF-β regulates immune and inflammatory responses by modulating leukocyte phenotype and activity. The effects of TGF-β on lymphocytes, monocytes, and macrophages can be either stimulatory or inhibitory, depending on microenvironmental cues, the state of cellular differentiation and the tissue origin of the cells,\textsuperscript{94} highlighting the pleotropic nature of the cytokine. TGF-β inhibits T and B lymphocyte proliferation,\textsuperscript{95} suppresses Th cell differentiation, and induces conversion of naïve T cells into Tregs.\textsuperscript{96} Femtomolar concentrations of TGF-β induce chemotaxis in peripheral blood monocytes,\textsuperscript{97} suggesting that it may play an important role in recruitment of mononuclear cells in inflamed tissues. Picomolar concentrations of TGF-β activate monocytes, stimulating synthesis of a variety of proinflammatory cytokines, chemokines, and growth factors\textsuperscript{90,97} and increasing integrin expression. In contrast to the activating effects of TGF-β on peripheral blood monocytes, its actions on mature macrophages are predominantly suppressive. TGF-β has a deactivating effect on macrophages, suppressing proinflammatory cytokine and chemokine synthesis\textsuperscript{90,99} and decreasing reactive oxygen generation. In vascular endothelial cells TGF-β inhibits cytokine-stimulated synthesis of adhesion molecules,\textsuperscript{100} attenuating lymphocyte\textsuperscript{101} and neutrophil\textsuperscript{102} adhesion to the endothelium. These TGF-β mediated effects may be important in suppression and resolution of the inflammatory response.

In addition to its effects on leukocytes, TGF-β is a potent modulator of fibroblast phenotype and function. TGF-β stimulation induces myofibroblast transdifferentiation\textsuperscript{103} and enhances synthesis of extracellular matrix proteins. Moreover, TGF-β suppresses the activity of proteases that degrade extracellular matrix by inhibiting MMP expression and by inducing synthesis of protease inhibitors, such as PAI-1 and TIMPs.\textsuperscript{104,105} Thus, through its broad immunomodulatory and anti-inflammatory properties and its profibrotic/matrix-preserving actions, TGF-β is an excellent candidate for a role as the “master switch” mediating suppression of postinfarction inflammation while promoting fibroblast activation and scar formation.\textsuperscript{106} Although this is an attractive hypothesis, the complex biology of TGF-β activation and its pleiotropic effects have hampered efforts to test the concept in experimental models of myocardial infarction.

TGF-β is markedly upregulated in experimental models of myocardial infarction\textsuperscript{107} where it is predominantly localized in the infarct border zone, associated with expression of its downstream intracellular effectors, Smad2, 3, and 4\textsuperscript{108} and phosphorylation of Smad1 and Smad2.\textsuperscript{109} Although evidence suggests that bioactive TGF-β is released in the cardiac extracellular fluids 3 to 5 hours following reperfused infarction,\textsuperscript{110} the mechanisms responsible for TGF-β activation in the infarcted heart are poorly understood. Induction of the matricellular protein TSP-1 in the infarct border zone may play an important role in activation of TGF-β signaling pathways in mouse and canine infarcts.\textsuperscript{43} In vivo, several studies have suggested important modulatory effects of TGF-β on the postinfarction inflammatory response. TGF-β injection during the inflammatory phase of healing significantly reduced ischemic myocardial injury, presumably by attenuating the deleterious effects of proinflammatory cytokines.\textsuperscript{111} Two independent studies showed that systemic inhibition of TGF-β signaling by injection of an adenovirus harboring soluble TGF-β type II receptor in the hindlimb muscles resulted in attenuated left ventricular remodeling by modulating cardiac fibrosis.\textsuperscript{112,113} However, early TGF-β inhibition increased mortality and exacerbated left ventricular dilation enhancing cytokine expression, suggesting that during the phase of resolution of the inflammatory response, TGF-β signaling may play an important role in suppression of inflammatory mediator synthesis.\textsuperscript{112}

Because of the pleiotropic effects of TGF-β on the inflammatory and reparative response following infarction, dissection of the signaling pathways responsible for its actions in...
the infarcted myocardium is essential for identification of therapeutic targets. TGF-β is capable of activating the canonical Smad-mediated pathway as well as a variety of Smad-independent pathways. Many studies have suggested that Smad3 signaling plays an essential role in fibrotic conditions; moreover, a growing body of evidence implicates Smad3 as a key mediator in TGF-β-induced suppression of inflammation. Recent investigations have attempted to dissect the role of Smad3 signaling in the postinfarction inflammatory and reparative response. Somewhat surprisingly, Smad3 null animals had markedly suppressed peak chemokine expression and decreased neutrophil recruitment in the infarcted myocardium and showed timely repression of inflammatory gene synthesis and resolution of the inflammatory infiltrate. Although myofibroblast density was higher in Smad3 null infarcts, interstitial matrix deposition in the peri-infarct zone and the noninfarcted myocardium was markedly reduced. In vitro, Smad3 signaling was essential for TGF-β-mediated myofibroblast differentiation and matrix synthesis but also exerted antiproliferative effects on cardiac fibroblasts. In the absence of Smad3 the infarct was filled with a large number of dysfunctional fibroblasts. Thus, TGF-β/Smad3 signaling does not appear to be involved in suppression and resolution of inflammation in healing infarcts but mediates interstitial fibrosis in the infarct border zone and in the noninfarcted myocardium. The role of noncanonical Smad-independent signaling in mediating TGF-β-induced suppression of postinfarction inflammation has not been investigated.

Recently, growth differentiation factor (GDF)-15, another member of the TGF-β superfamily, has been identified as a crucial endogenous mediator involved in suppression of the inflammatory response associated with myocardial infarction. GDF-15 is upregulated in the infarcted myocardium, primarily localized in cardiomyocytes of the infarct border zone. GDF-15−/− mice had a high incidence of cardiac rupture following myocardial infarction associated with accentuated recruitment of neutrophils. GDF-15 restrains inflammation by counteracting conformational activation of neutrophil β2 integrins, thus preventing excessive chemokine-activated leukocyte arrest on the endothelium.

Clinical Implications: Is Adverse Remodeling in Patients With Myocardial Infarction Due to Defective Suppression and Impaired Resolution of Inflammation?

Ample evidence from experimental models of myocardial infarction suggests that defects in pathways involved in timely suppression, resolution, and containment of the postinfarction inflammatory response result in adverse remodeling of the infarcted heart. In addition to the experimental findings, the fundamental biology of inflammation suggests catastrophic consequences of an uncontrolled postinfarction inflammatory response on myocardial structure and function providing a strong theoretical basis to support the notion that prolonged or expanded inflammation would result in adverse outcome. Thus, there is little doubt that unrestrained inflammation is deleterious for the infarcted heart. However, to support the therapeutic importance of this concept, a key question needs to be answered: To what extent is defective negative regulation of the inflammatory response responsible for adverse remodeling and worse outcome in patients with acute myocardial infarction? Obviously, considering the difficulties in assessment of myocardial inflammation in human patients with acute myocardial infarction, this question is particularly challenging. However, emerging evidence from clinical trials may support a role for uncontrolled inflammation as a determinant of adverse outcome following myocardial infarction. In the A to Z study, persistently elevated serum MCP-1 levels in patients with acute coronary syndromes were independently associated with reduced survival; the increased mortality in patients with sustained systemic inflammation was not due to new coronary events. The study did not examine the relation between MCP-1 levels and cardiac remodeling. However, one could hypothesize that persistently elevated serum chemokine levels may identify patient subpopulations with defective repression of proinflammatory signaling following myocardial infarction that results in accentuated remodeling and adverse outcome.

Targeting the Inflammatory Response in Patients With Acute Myocardial Infarction

The idea of targeting the inflammatory response in patients with myocardial infarction is not new. Twenty to 30 years ago extensive experimental evidence derived primarily from research in large animal models suggested that early infiltration of the infarcted myocardium with leukocytes induces cytotoxic injury on viable cardiomyocytes extending ischemic damage. These findings fueled several clinical trials aimed at protecting the ischemic myocardium through early inhibition of key inflammatory signals. The catastrophic effects of methylprednisolone administration in patients with acute myocardial infarction highlighted the need for more selective anti-inflammatory approaches in order to achieve effective suppression of injurious processes without interfering with the reparative response. Thus, later efforts were focused on pharmacological inhibition of selected molecular targets that mediate recruitment of leukocytes in the infarcted myocardium. Unfortunately, both anti-CD18 integrin approaches and complement inhibition strategies produced disappointing results in clinical trials raising concerns regarding the usefulness of strategies targeting the inflammatory cascade in myocardial infarction. Considering the extensive evidence supporting their effectiveness in experimental animal models, what is the basis for failure of targeted anti-inflammatory strategies in reducing ischemic cardiac injury?

First, although animal models provide important information in dissecting pathophysiologic mechanisms, their ability to predict the success of a specific approach in human patients is limited. The complexity of the clinical context cannot be simulated by experimental studies. A well-designed animal investigation aims at testing a specific hypothesis on the biological role of a mediator, or pathway, by eliminating confounding variables that may affect outcome. In the clinical context, variables such as age, gender, genetic variations between individuals, the presence of comorbid conditions such as diabetes, obesity, and hypertension, the timing of reperfusion, and the presence of distinct patterns of coronary
disease greatly complicate prediction of the potential effects of a therapeutic intervention. Studies examining the effects of aging on the postinfarction inflammatory response have provided insight into the challenges of predicting the effects of a therapeutic intervention on the basis of experimental animal studies. In senescent mice, increased dilative remodeling was associated with suppressed and prolonged inflammation, and defective scar formation due, at least in part, to impaired responses of fibroblasts to fibrogenic growth factors. Because experimental infarction studies are almost always performed in young adult animals that exhibit robust inflammatory responses, the injurious potential of inflammatory mediators in patients with myocardial infarction may have been overstated due to extrapolation of the findings to the middle-aged or elderly human patients with myocardial infarction.

Second, the postinfarction inflammatory cascade is dependent on a complex network of molecular mediators with pleiotropic effects, dictated by contextual factors and by critical spatial and temporal variables. Inflammatory signals that may appear reasonable therapeutic targets considering their injurious role in the early stages of the inflammatory response may also be essential regulators of cardiac repair. Thus, interventions attenuating early inflammatory injury may also result in impaired healing, leading to accentuated adverse remodeling through alterations in the properties of the scar. For many anti-inflammatory strategies, the possible benefit from reduction of inflammatory cardiomyocyte injury may not outweigh detrimental effects on the reparative response. Furthermore because of the distinct pathological processes in the infarct, the border zone and the remote remodeling myocardium, spatial localization of the therapeutic intervention is a critical determinant of its success.

Third, it should be noted that the strength of experimental evidence supporting the use of anti-inflammatory approaches varies. Thus, the effectiveness of antidcomplement approaches was primarily supported by neutralization studies. Anti-integrin strategies, on the other hand, were supported by antibody inhibition studies and loss-of-function genetic models. Stronger experimental evidence derived from both loss-of-function and gain-of-function approaches supports the effectiveness of inhibiting the IL-1 system following myocardial infarction. The promising early findings from a pilot study administering anakinra, the recombinant form of the IL-1 receptor antagonist, in patients with ST elevation myocardial infarction may reflect the higher likelihood of success of approaches with a higher level of validation.

Our growing knowledge on the regulation of the inflammatory response in the healing infarct suggests that the significance of acute inflammatory cardiomyocyte injury following myocardial infarction may have been overstated. Although early investigations using antibody neutralization strategies in large animal models suggested detrimental effects of postinfarction inflammation, later studies in murine models have challenged the concept of “leukocyte-mediated cytotoxic injury” demonstrating that animals with genetic disruption of genes with a critical role in the inflammatory response (such as ICAM-1/P-selectin and IL-1RI) had no increase in infarct size despite marked attenuation of leukocyte infiltration.

Thus, direct inflammatory cardiomyocyte injury may not be significant; however a growing body of evidence suggests that disruption of inflammatory pathways may protect the heart by preventing adverse remodeling through effects on reparative cells and on matrix metabolism. Targeting the inflammatory reaction remains promising; however, the focus of our therapeutic strategies should be shifted to a new direction to ensure optimal temporal and spatial regulation of the inflammatory response preventing uncontrolled or prolonged inflammation. From this perspective, the early disruption of key inflammatory signals attempted in some clinical trials may in fact prolong inflammation by preventing removal of dead cells and matrix debris leading to impaired wound healing, accentuated remodeling, and adverse outcome. Identification of novel therapeutic targets requires intensification of our research efforts in 2 main areas. First, using carefully selected experimental models we need to understand the mechanisms involved in repression and resolution of the postinfarction inflammatory response and study the relation between specific defects in negative regulation of inflammation and cardiac remodeling. Second, using suitable biomarkers we need to identify patients exhibiting defective resolution of inflammation following myocardial infarction; these subpopulations may be ideal candidates for targeted anti-inflammatory approaches to inhibit excessive or prolonged inflammation. Understanding the STOP signals involved in suppression of inflammation following infarction may be the key to prevent adverse remodeling and progression to heart failure.

Sources of Funding
Dr Frangogiannis’ laboratory is funded by National Institutes of Health grants R01 HL-76246 and R01 HL-85440 and by the Wilf Family Cardiovascular Research Institute.

Disclosures
None.

References


25. Suzuki K, Murtuza B, Smolenski RT, Sammut IA, Suzuki N, Kaneda Y, Yacoub MH. Overexpression of interleukin-1 receptor antagonist...


Frangogiannis  Inflammation and Cardiac Repair 173


Regulation of the Inflammatory Response in Cardiac Repair
Nikolaos G. Frangogiannis

Circ Res. 2012;110:159-173
doi: 10.1161/CIRCRESAHA.111.243162

Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2012 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circres.ahajournals.org/content/110/1/159

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org//subscriptions/